News
03-24-2015, 10:17 PM
Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.
More... (http://www.news-medical.net/news/20150325/TPUs-submission-of-Docetaxel-Injection-Concentrate-Non-Alcohol-Formula-NDA-acknowledged-by-FDA.aspx)
More... (http://www.news-medical.net/news/20150325/TPUs-submission-of-Docetaxel-Injection-Concentrate-Non-Alcohol-Formula-NDA-acknowledged-by-FDA.aspx)